Your session is about to expire
← Back to Search
Cannabinoid
Low dose RLS103 for Social Anxiety Disorder
Phase 1
Waitlist Available
Research Sponsored by Receptor Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 minutes, assessed at visit 2 and visit 3
Awards & highlights
Study Summary
This trial is testing a new drug to see if it can help people with social anxiety disorder during a public speaking challenge.
Eligible Conditions
- Social Anxiety Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 minutes, assessed at visit 2 and visit 3
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 minutes, assessed at visit 2 and visit 3
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence and severity of adverse events
Secondary outcome measures
Change in CGI
Change in subject-reported anxiety
Other outcome measures
Changes in blood pressure in subjects with SAD
Changes in pulse rate in subjects with SAD
Changes in respiratory rate in subjects with SAD
Trial Design
3Treatment groups
Experimental Treatment
Group I: placeboExperimental Treatment1 Intervention
placebo inhaled dry powder
Group II: Low dose RLS103Experimental Treatment1 Intervention
3 mg CBD inhaled dry powder
Group III: High dose RLS103Experimental Treatment1 Intervention
6 mg CBD inhaled dry powder
Find a Location
Who is running the clinical trial?
Receptor Life SciencesLead Sponsor
1 Previous Clinical Trials
2 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger